Integrated In Silico, In Vitro, and In Vivo Studies Reveal Mangiferin as a Promising Antiviral Agent Against H1N1/pdm2009 Influenza Virus.

ABSTRACT: The ongoing global threat posed by the influenza A virus, exacerbated by antigenic drift and the emergence of antiviral resistance, accentuates the urgent need for innovative therapeutic strategies. Through molecular docking, this study revealed that mangiferin has a strong binding affinity for the active site of the neuraminidase (NA) protein of influenza virus A(H1N1)pdm09, with a binding energy of -8.1 kcal/mol. In vitro assays confirmed a dose-dependent inhibition of NA, with an IC₅₀ of 88.65 μM, and minimal cytotoxicity, as indicated by a CC₅₀ of 328.1 μM in MDCK cells. In murine models, the administration of mangiferin at a dosage of 25 mg/kg significantly mitigated weight loss, decreased viral loads in nasal turbinates and lungs by over 1 log10 TCID₅₀

SUBMITTER: Gan Y 

PROVIDER: S-EPMC12299334 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature